Joseph G. Pressey · Pazopanib therapy for desmoid tumors in adolescent and young adult patients
Follow
Article1 min read·Published Jan 2018Older

Pazopanib therapy for desmoid tumors in adolescent and young adult patients

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2018 · 1 min read

In brief

In brief

This retrospective study evaluates pazopanib as a targeted therapy for desmoid tumors in adolescent and young adult patients who failed conventional treatments. Pazopanib demonstrated superior response rates compared to established therapies including surgery, vinblastine/methotrexate, and sulindac/tamoxifen, with partial responses in multiple cases and dramatic volumetric tumor reduction.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: Desmoid tumors/aggressive fibromatosis (DT/AF) lack a reliably effective medical therapy. Surgical resection may be morbid and does not preclude recurrence. Radiation may carry severe late effects, particularly detrimental in young patients. At our institution, we recently observed promising results with pazopanib therapy for DT/AF in adolescent and young adult (AYA) patients. Procedure: Retrospective single-institution chart review. Results: Six DT/AF patients of 3-21 years with previously treated DT/AF received pazopanib; 31 DT/AF patients received established therapies only. In both groups, median age at diagnosis was 16 years, female patients comprised 50%, and most common DT/AF site was extremity. Established therapies showed few objective responses and most patients therefore received multiple therapies. Surgical resection had a 68% recurrence rate. Of eight patients who received vinblastine/methotrexate, only one had a partial response (PR) by RECIST 1.1 and five had stable disease (SD); 62.5% required additional therapy. Of seven patients who received sulindac/tamoxifen, none showed objective improvement. In contrast, pazopanib demonstrated best responses by RECIST of PR in two of seven and SD in six of seven tumors. A PR of 66% was observed in a patient who had failed multiple prior therapies. The mesenteric DT/AF also showed PR. Maximum volumetric decrease by T2-weighted magnetic resonance imaging (MRI) was 97%. Dramatically increased fibrosis was seen o

Statements in this article

  1. Surgical resection of desmoid tumors had a 68% recurrence rate in this cohort.

    ResearchResults
  2. Of eight patients who received vinblastine/methotrexate, only one had a partial response by RECIST 1.1 and five had stable disease.

    ResearchResults
  3. 62.5% of patients treated with vinblastine/methotrexate required additional therapy.

    ResearchResults
  4. Of seven patients who received sulindac/tamoxifen, none showed objective improvement.

    ResearchResults
  5. Pazopanib demonstrated best responses by RECIST of partial response in two of seven and stable disease in six of seven tumors.

    ResearchResults
  6. A partial response of 66% was observed with pazopanib in a patient who had failed multiple prior therapies.

    ResearchResults
  7. Mesenteric desmoid tumor showed partial response to pazopanib.

    ResearchResults
  8. Maximum volumetric decrease by T2-weighted MRI with pazopanib therapy was 97%.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.